I. MODIFIED AGREEMENTS

Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)

AnorMED Inc. (Canada; TSE:AOM)

Shire Pharmaceuticals Group plc

Expanded agreement under which Shire gets worldwide rights to Fosrenol for all human and veterinary uses

AnorMED is getting $180,000 up front and would get royalties on sales; the product is lanthanum carbonate, for high phosphate levels (1/13)

BioCryst Pharmaceuticals Inc. (BCRX)

Johnson & Johnson

BioCryst transferred rights to compounds from their October 1996 collaboration on drugs affecting the complement system to J&J unit 3-Dimensional Pharmaceuticals Inc.

The deal was ended in October 2003; BioCryst will get an initial payment and would get royalties on sales; specific terms were not disclosed (12/23)

Biotique Systems*

Berlex Biosciences Integration System

Expanded deal under which all Schering AG companies get access to the Biotique Local

The subscription runs three years and expands a deal with Berlex, a unit of Schering; terms were not disclosed (1/19)

Comgenex Inc.* (Hungary)

Bayer AG (Germany)

Companies renewed their exclusive chemistry collaboration for sixth straight year

Comgenex will focus on improving properties of compound libraries; terms were not disclosed (11/25)

Compugen Ltd. (Israel; CGEN)

Abbott Laboratories

Extended deal under which Abbott uses Compugen technology for identification of drug targets across multiple therapeutic areas

Abbott will receive several updates of Compugen's Genecarta genome, transcriptome and proteome database; terms were not disclosed (2/18)

Cortex Pharmaceuticals Inc. (AMEX:COR)

Les Laboratoires Servier (France)

Companies extended December 2000 research collaboration for two years in the area of Ampakine compounds

Cortex will get $4.3M in support over the two years, and support would continue until either wants to end the agreement (1/20)

Discovery Partners International Inc. (DPII)

Allergan Inc.

Companies expanded R&D relationship by entering lead-finding collaboration

Deal centers on enzyme and GPCR targets in ophthalmology and neurology; terms were not disclosed (12/4)

Entelos Inc.*

Johnson & Johnson Pharmaceutical Research and Development LLC

Expanded collaboration to include target validation, lead optimization and clinical development in obesity

Companies are members of the Diabetes Research Forum; terms of the deal were not disclosed (12/9)

Genedata AG* (Switzerland)

Schering AG (Germany)

Schering extended its license for Expressionist, the Genedata computational system for large- scale gene expression analysis

They have been partners since 1999; terms of the deal were not disclosed (1/14)

Gene Logic Inc. (GLGC)

Sumitomo Pharmaceuticals Co. Ltd. (Japan)

Sumitomo renewed its deal to use Gene Logic's information services for three years

Sumitomo retains access to the BioExpress database and has limited rights to the newer Ascenta System; terms were not disclosed (1/8)

GeneProt Inc.* (Switzerland)

Novartis Pharma AG (Switzerland)

Amended October 2000 deal to accelerate delivery of proteins to Novartis

GeneProt will will continue to use its large- scale proteomics platform in the effort; terms were not disclosed (2/5)

Human Genome Sciences Inc. (HGSI)

Pfizer Inc.

Pfizer licensed nonexclusive rights to develop products based on gene sequences from Staphylococcus aureus

The agreement amends a 1996 deal HGS signed with Pharmacia & Upjohn Inc., now part of Pfizer Inc.; Pfizer is making a onetime payment and is relieved of any other obligation under the deal (12/18)

Ligand Pharmaceuticals Inc. (LGND)

TAP Pharmaceutical Products Inc.

One-year extension of deal focused on selective androgen receptor modulators

The collaboration began in 2001; specific terms of the the extension were not disclosed (12/22)

Metabolex Inc.*

Pfizer Inc.

Companies extended by one year their collaboration for developing drugs for Type II diabetes

Metabolex gets research funding and would get royalties on sales; terms were not disclosed; the deal dates back to 1998 (1/21)

Myriad Genetics Inc. (MYGN)

Abbott Laboratories

Expanded alliance to include a broad new pharmacogenetics program, focused on identifying genetic variations around drug targets in development

Abbott will fund research and own resulting findings; Myriad has first rights on personalized products for reference labs (1/7)

Neurion Pharmaceuticals Inc.*

Pfizer Inc.

Deal to renew and expand December 2002 agreement through 2004

The work includes modeling of drug binding to the HERG potassium ion channel and evaluation of Pfizer compounds using Neurion's NP2 technology; Neurion will get research funding (1/8)

NitroMed Inc. (NTMD)

Boston Scientific Corp.

Extended collaboration on development of nitric oxide- coated stents

NitroMed received $3M as the deal was extended through 2005 and could get milestone and royalty payments (1/8)

Peptech Ltd. (Australia; ASX:PTD)

Abbott Laboratories

Companies resolved a dispute by renegotiating royalty rate on Humira

The deal still needed final approval; terms were not disclosed (12/24)

Stressgen Biotechnologies Corp. (Canada; TSE:SSB)

F. Hoffmann-La Roche Ltd. (Switzerland)

Restructured deal to develop heat-shock proteins by adding indications and expanding the scope of the deal

The potential value of payments to Stressgene increased $13M to $227M; it also gets rights to record certain sales revenues (12/2)

Structural GenomiX Inc.*

Eli Lilly and Co.

Expanded agreement to provide Lilly long-term access to the SGX synchrotron beamline facility to support drug discovery

SGX will generate crystal structure data on Lilly drug targets and compounds, and get up-front fees and annual operating costs; specific terms were not disclosed (1/15)

Sunesis Pharmaceuticals Inc.*

Johnson & Johnson Pharmaceutical Research & Development LLC

Companies extended for one year their collaboration on small-molecule enzyme inhibitors for chronic diseases

Sunesis gets research funding and could get additional R&D milestones, as well as royalties on sales; specific terms were not disclosed (1/15)

Symyx Technologies Inc. (SMMX)

Merck & Co. Inc.

Symyx will develop and deliver a workflow system in the area of biocatalysis

It is the the fifth Symyx Discovery Tool purchased by Merck; terms of the deal were not disclosed (1/15)

Third Wave Technologies Inc. (TWTI)

BML Inc. (Japan)

Extended partnership for at least one year on molecular diagnostic tests for infectious diseases, genetic testing and pharmacogenomics

The deal, using Third Wave's Invader technology, began in December 2000; terms were not disclosed (1/8)

Tripos Inc. (TRPS)

Pfizer Inc.

Amended deal under which Tripos will reduce file enrichment activities, but do new work in the areas of hit follow-up and large library production

The changes are expected to result in a 10% reduction in the contract's value, which was valued at up to $100M over four years when signed in January 2002 (1/29)

II. TERMINATED AGREEMENTS

Cambridge Antibody Technology Group plc (UK; LSE:CAT)

Elan Corp. plc (Ireland)

CAT exercised its right to terminate the three-year-old collaboration focused on research on multiple targets

Ending the exclusive deal allows CAT the opportunity to collaborate with others in the fields of neurology and pain (2/9)

Celltech Goup plc (UK; LSE:CCH)

Pfizer Inc.

Celltech regained full rights to CDP 870, a pegylated anti-TNF-alpha antibody fragment

Celltech refused to make requested changes to the March 2001 collaboration; Celltech is deciding on development and partnership plans (12/1)

Debiopharm SA* (Switzerland)

Pfizer Inc.

Trelstar one- and three-month formulation of luteinizing hormone-releasing hormone or prostate cancer

Debiopharm reacquired rights to the products, which are approved by the FDA; Debiopharm plans to find another partner (12/2)

PPL Therapeutics plc (UK; LSE:PTH)

AstraZeneca plc (UK)

Ended deal on recombinant bile salt stimulated lipase

Following termination PPl sold the assets to Swedish company Arexis AB for about $280,000 in cash (2/11)

Notes:

^# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange.